Stakeholder assessment of the evidence for cancer genomic tests

Stakeholder Assessment of the Evidence for Cancer Genomic Tests

Twenty-two stakeholders participated in a workshop exploring the evidence of genomic tests for clinical and coverage decision-making.

Correction: Corrigendum: Stakeholder assessment of the evidence ...

Correction: Corrigendum: Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. Genetics in Medicine volume 15 ...

Stakeholder assessment of the evidence for cancer genomic tests ...

Cancer Genomics · Genomic Test · Stakeholder Assessment · Oncotype DX · Malignant Neoplasm · Epidermal Growth Factor Receptor · Medicine · Hereditary Nonpolyposis ...

Stakeholder Assessment of the Evidence for Cancer Genomic Tests ...

PDF | Purpose: Insufficient evidence on the net benefits and harms of genomic tests in real-world settings is a translational barrier for genomic.

Stakeholder assessment of the evidence for cancer genomic tests ...

Stakeholders' assessment of the current evidence base for clinical practice and coverage decisions should be a critical step in influencing research, ...

Resource Center | CMTP

Stakeholder Assessment of the Evidence for Cancer Genomic Tests: Insights from Three Case Studies (December 2012). Deverka PA, Schully SD, Ishibe N, et al.

2 Stakeholder Perspectives on Evidence

... evaluation criteria that TEC uses for its assessment of genetic test evidence. ... Cancer Center looks at genomic diagnostic tests from the perspective of value.

a novel framework for stakeholder-informed prioritization of cancer ...

The findings provide a basic framework for systematically prioritizing genomic technologies for additional evaluation and illustrate the potential impact of ...

Stakeholders' views on the value of outcomes from clinical genetic ...

Robust evidence about the value of clinical genomic interventions (CGIs), such as genetic/genomic testing or clinical genetic evaluation, is limited. We ...

Erratum: Stakeholder assessment of the evidence for cancer ...

Fingerprint. Dive into the research topics of 'Erratum: Stakeholder assessment of the evidence for cancer genomic tests: Insights from three case studies ...

engaging regulatory stakeholders in clinical genomics research

... assessment processes of these stakeholders ... Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies.

Facilitating comparative effectiveness research in cancer genomics

A vocal minority of stakeholders were particularly adamant that the engagement process should occur more quickly, with more efficient ...

Stakeholder answers (during the meeting) to “At this time, what ...

table 1 Suggestions for future research · Stakeholder Assessment of the Evidence for Cancer Genomic Tests: Insights from Three Case Studies. Article. Full-text ...

Stakeholder participation in comparative effectiveness research

The first step in generating evidence for the stakeholder engagement process was a landscape analysis to identify candidate genetic tests to ...

Clinical Utility of Genomic Testing in Cancer Care - ASCO Publications

Applying this expanded definition will encourage evidence-based use of genomic testing in cancer care by helping physicians and other health ...

Providing guidance for genomics-based cancer treatment decisions

We engaged a total of 22 stakeholders, including: prostate cancer patients, urological surgeons, radiation oncologists, genomic testing industry ...

Building the Evidence Base for Decision-making in Cancer Genomic ...

Background—The clinical utility is uncertain for many cancer genomic applications. Comparative effectiveness research (CER) can provide evidence to clarify this ...

ESMO Recommendations on clinical reporting of genomic test ...

Genomic tumour profiling has a crucial role in the management of patients with solid cancers, as it helps selecting and prioritising ...

Stakeholders' views on the value of outcomes from clinical genetic ...

tests, genetic evaluation ... American Society of Clinical. Oncology policy statement update: genetic and genomic testing for cancer ...

Chapter: 7 Panelists' and Stakeholders' Perspectives

A major hurdle to genomic-based medicine is the lack of a national, dynamically updated, interpretative database of evidence for the clinical utility of genetic ...